Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010.
Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010.
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens